Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
Cyramza® (ramucirumab): Administration Using Filter
Administer ramucirumab via infusion pump. A separate infusion line must be used for the infusion and the line must be flushed with sterile sodium chloride (0.9%) solution for injection at the end of the infusion.
The filter is recommended to remove any possible particles (which include micro-organisms) that may have been inadvertently introduced during the preparation for infusion. Ramucirumab is compatible with a 0.2 micron protein sparing (low protein binding) filter and a 0.2 micron protein sparing (low protein binding) filter of at least 4.2 cm2 surface area may be used for administration.1
Use of the Same Filter
In clinical studies, when ramucirumab was administered in combination with another treatment, the filter was changed between the administration of ramucirumab and the administration of other products.1 Please refer to the local labeling for other products for details on administration.
Administration Using the Same Infusion Line
It is acceptable to use a single/same IV line to administer ramucirumab either before, or after, another medication if the infusion line used is properly flushed with normal saline prior to administering the ramucirumab through the same line.1
IV = intravenous
Date of Last Review: April 17, 2020